Who is sponsoring NCT07530159?

NCT07530159 is sponsored by Fátima Hinojosa Ramírez.

What drugs are being tested in NCT07530159?

Interventions in NCT07530159: Retromuscular ventral hernia repair, Polypropylene mesh, Standard perioperative care.

What condition does NCT07530159 study?

NCT07530159 studies Ventral Hernia Repair.

Is NCT07530159 still recruiting?

NCT07530159 is currently active, enrolled. Last updated 15 April 2026.

Last reviewed 2026-04-15 · How we verify

NCT07530159: ECOHERNIA-3

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cost-Effectiveness of Retromuscular Hernia Repair

Active, enrolled NA Last updated 15 April 2026

What this trial tests

NA trial testing Retromuscular ventral hernia repair in Ventral Hernia Repair in 120 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

1 January 2026

Primary endpoint
1 January 2028

1 January 2029

Quick facts

Lead sponsor	Fátima Hinojosa Ramírez
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	health services research
Enrollment	120
Start date	1 January 2026
Primary completion	1 January 2028
Estimated completion	1 January 2029
Sites	1 location across Spain

Drugs / interventions tested

Retromuscular ventral hernia repair
Polypropylene mesh
Standard perioperative care

Conditions studied

Ventral Hernia Repair — all drugs for Ventral Hernia Repair →

Sponsor

Fátima Hinojosa Ramírez

Who can join

18 and older, any sex, with Ventral Hernia Repair. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This prospective observational study aims to evaluate the clinical outcomes and cost-effectiveness of retromuscular midline ventral hernia repair using open, laparoscopic and robotic approaches. Patients undergoing elective repair are included and followed to assess postoperative complications, length of hospital stay, recurrence and quality of life. In addition, a cost-effectiveness analysis will be performed from the perspective of the Spanish National Health System. The study is currently ongoing.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07530159 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fátima Hinojosa Ramírez
Last refreshed: 15 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07530159.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing